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Abstract
Detection of Mycobacterium tuberculosis antigens in urine is attractive as a potential means of diagnosing tuberculosis (TB)
regardless of the anatomical site of disease. The most promising candidate antigen is the cell wall lipopolysaccharide
antigen lipoarabinomannan (LAM), which has been used to develop commercially available enzyme-linked
immunosorbent assays. Although highly variable diagnostic accuracy has been observed in different clinical populations,
it is now clear that this assay has useful sensitivity for diagnosis of HIV-associated TB in patients with advanced
immunodeficiency and low CD4 cell counts. Thus, this assay is particularly useful when selectively used among patients
enrolling in antiretroviral treatment services or in HIV-infected patients requiring admission to hospital medical wards.
These are the very patients who have the highest mortality risk and who stand to gain the most from rapid diagnosis,
permitting immediate initiation of TB treatment. A recently developed low-cost, lateral-flow (urine ‘dip-stick’) format of the
assay provides a result within 30 minutes and is potentially a major step forward as it can be used at the point-of-care,
making the possibility of immediate diagnosis and treatment a reality. This paper discusses the likely utility of this point-
of-care assay and how it might best be used in combination with other diagnostic assays for TB. The many further
research studies that are needed on this assay are described. Consideration is particularly given to potential reasons for
the variable specificity observed in existing field evaluations of LAM ELISAs. Whether this might be related to the assay
itself or to the challenges associated with study design is discussed.
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Introduction
Tuberculosis (TB) remains a major challenge to global
health [1]. There were an estimated 8.8 million incident
cases in 2010 and, of 1.45 million TB deaths, 0.35 mil-
lion were in HIV-positive people [2]. The HIV-asso-
ciated TB epidemic has been one of the major
stumbling blocks to TB control, accounting for an esti-
mated 12.5% of the global TB caseload in 2010. A large
majority (82%) of these cases were concentrated in sub-
Saharan Africa where HIV has had an extraordinary im-
pact on TB incidence rates and TB-related mortality
[2,3].
Despite the fact that low-income and middle-income
countries account for over 90% of the worldwide burden of
TB, these regions still rely heavily on sputum smear micros-
copy and chest radiology for TB diagnosis [1,4]. These tech-
niques often perform poorly and are typically unavailable at
patients’ first point of contact with the health system.
Moreover, the diagnostic accuracy of these techniques is
substantially impaired in those with HIV coinfection [4,5].
Although simple point-of-care assays are available and rou-
tinely used for diagnosis of HIV infection and malaria [6],
this is not the case for TB. There is a huge need for rapid
point-of-care tests for TB with high diagnostic accuracy
that can be readily used at all levels of the health system
and in the community.
Urine antigen testing for TB diagnosis
Mycobacterium tuberculosis antigen detection has long
been viewed positively as an option for TB diagnosis as
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this has the potential advantage of reflecting mycobacterial
burden while remaining unimpaired by immune status.
Moreover, analysis of urine rather than sputum samples is
a very attractive option as urine is simple to collect with-
out generating hazardous bioaerosols, it is safe to handle
in the laboratory, it has relatively few bacterial contami-
nants and sample quality is unlikely to be highly variable.
A number of mycobacterial antigens can be
detected in the urine of patients with pulmonary TB
[7,8], but the most promising of these to emerge is
the cell wall lipopolysaccharide lipoarabinomannan
(LAM) [9-11]. Enzyme-linked immunosorbent assays
(ELISAs) that detect LAM have been commercially
available as TB diagnostic assays for a number of
years [9]. More recently a simple, low-cost lateral
flow version of this assay has been developed and
the first clinical evaluations have been published
[12,13]. This paper reviews the utility of assays for
urinary LAM for diagnosing HIV-associated TB in
adults and discusses the potential of the lateral-flow
LAM assay. Rigorous field evaluations of this assay
are needed and we discuss the associated challenges
in study design.
What is lipoarabinomannan (LAM)?
LAM is one of three major groups of interrelated
lipopolysaccharides within the mycobacterial cell wall
[14-16]. All these molecules are non-covalently
attached to the mycobacterial plasma membrane via
the glyco-phospholipid anchor and extend to the
surface of the cell wall. LAM molecules have three
major structural domains (Figure 1). The phospho-
lipid anchor is linked to a carbohydrate (mannose)
core, which is conserved across all mycobacterial
species, and from this carbohydrate (arabinofurano-
syl) side-chains arise [14]. Variable capping of the
arabinosyl side-chains with mannose residues results
in a diversity of LAM molecules with a range of
unique properties and functions. The presence of
mannose capping allows mycobacteria to bind to
mannose receptors on macrophages, which provide
the preferred intracellular environment for the or-
ganism [14].
The pattern of capping characterises these LAM mole-
cules as belonging to one of three major classes. LAM
molecules with mannosylated caps on the terminal D-
arabinan side chains (ManLAM) are characteristic of
more pathogenic mycobacterial species such as M. tu-
berculosis, Mycobacterium leprae and Mycobacterium
bovis [14]. These molecules serve as major virulence fac-
tors, causing inhibition of a range of processes including
phagosome maturation, apoptosis, interferon-γ-signal-
ling in macrophages and interleukin-12 secretion by
dendritic cells and also serving as a scavenger for toxic
oxygen free radicals [14,17]. Thus, LAM plays an im-
portant role in promoting survival of M. tuberculosis in
the human host.
While ManLAMs are found in pathogenic species,
LAM capped with phosphoinositol (so-called PILAMs)
are typically found in non-pathogenic species such as
Mycobacterium smegmatis [14]. Other species of rap-
idly growing mycobacteria such as Mycobacterium
chelonae contain LAMs have no mannose or
phosphoinositol capping and are termed AraLAM
molecules. AraLAM and PILAM have a strong proin-












Figure 1 Cartoon showing the basic structure of mycobacterial lipoarabinomannan (LAM) and its three main domains. (i) The
glycophospholipid anchor binds the molecule to the plasma membrane of the organism. (ii) The mannan core is attached to this and is highly
conserved across mycobacterial species. (iii) The variable branching arabinan side chains and the variable mannose capping of these side chains
gives rise to the diversity of LAM molecules.
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ManLAM molecules have potent immunomodulatory
properties.
LAM from any particular source is heterogeneous with
regard to size, the pattern of branching of the side-
chains and acylation and phosphorylation of the mannan
core and the arabinan side chains [14]. The peak mo-
lecular weight has been found to be centered at
17.3 kDa, but with a broad distribution either side,
reflecting considerable molecular heterogeneity [18].
This diversity of the LAM family of molecules is of im-
portance with regard to the sensitivity and specificity of
immunoassays for LAM. LAM is heat-stable and so does
not readily degrade in clinical samples, increasing its
suitability as a diagnostic target.
How does LAM enter the urine?
LAM can be recovered in large quantities from cultures
of M. tuberculosis (15 mg per gram of bacteria) in vitro
[16] and there is some evidence to suggest that LAM is
actively secreted from infected alveolar macrophages
[17]. Such an active process would be consistent with
the important immunomodulatory properties of LAM
that are likely to favour survival of the organism in vivo.
Development of high tissue concentrations of LAM at
anatomic sites of disease may favour entry of the antigen
into the systemic circulation such that LAM can be
detected in serum samples from patients with pulmon-
ary TB [19]. Systemic antigenaemia may also result dir-
ectly from dissemination of M. tuberculosis in the blood
stream, especially in patients with advanced HIV-asso-
ciated immunodeficiency [20].
The mechanism whereby LAM enters the urine from
the systemic circulation is unclear. LAM has a similar
molecular size to myoglobin, which readily passes into
urine from the bloodstream following release from
damaged muscles in people with normal renal glomeru-
lar function [21]. Thus, it is possible that free LAM
molecules might similarly enter urine in this way. How-
ever, LAM is antigenic, eliciting a strong humoral anti-
body response [22] and so it is likely that LAM largely
exists within the circulation in the form of circulating
immune complexes which would not readily cross the
glomerular basement membrane. The proportions of
complexed and uncomplexed LAM in blood may be an
important determinant of LAM-antigenuria and thus de-
ficiencies in the humoral immune responses to LAM
could theoretically be an important determinant of anti-
genuria. Similarly, whether LAM within urine is anti-
body-bound may also be important as LAM within
immune complexes may be difficult for immunoassays
to detect due to steric hindrance.
It has been postulated that renal dysfunction (such as
HIV nephropathy) may underlie the ability of LAM to
enter the urine from the bloodstream. A study from
Tanzania found that detection of any protein in urine
samples by simple urinalysis stick tests was associated
with LAM antigenuria [23] whereas similar testing in a
study in South Africa found no such association [24]. A
more careful analysis using laboratory quantification of
urine protein excretion found that successful detection
of LAM in the urine of patients with TB was not asso-
ciated with heavy proteinuria that would be indicative of
severe glomerular dysfunction that would be required to
permit free filtration of immune-complexed LAM [25].
This would therefore suggest that this is not an import-
ant factor.
Recent studies of patients with HIV-associated TB and
LAM detectable in the urine have found that, even using
small urine aliquots, approximately one half of these
urine samples test positive by Xpert MTB/RIF assay
[25,26]. In contrast, LAM-negative samples from TB
patients all tested Xpert MTB/RIF-negative [25]. Since
Xpert MTB/RIF detects whole M. tuberculosis bacilli,
positive results using this assay indicate the presence of
M. tuberculosis in the renal tract of these patients.
In conclusion, it seems possible that free circulating
LAM could enter the urine readily, but not if present in
large immune complexes. LAM antigenuria, however,
could also potentially result from direct involvement of
the renal tract with TB such that antigen may enter the
urinary tract directly without passing across the renal
glomerular basement membrane.
Clinical evaluation of commercial ELISAs
Early studies demonstrated the ability to detect LAM in
the sputum, serum and urine from patients with TB
[19,27-29], giving moderate diagnostic sensitivity and
specificity. However, these assays required extensive
sample preparation, which included column chromatog-
raphy, rendering them impractical for routine clinical
diagnosis. However, with proof of principle data from a
simplified polyclonal sandwich ELISA test that required
much less intensive sample processing, the first ELISA
was released onto the commercial market [30]. This was
initially produced by Chemogen Inc. as the ‘MTB ELISA’
test and was subsequently marketed as ‘Clearview TB
ELISA’ by Inverness Medical Innovations and latterly by
Alere Inc. Sample preparation for these assays requires
heating the urine sample to 95–1000 C for 30 minutes
and then centrifugation at 10,000 rpm for 15 minutes at
room temperature. The supernatant is then tested in a
96 well plate format ELISA.
Nine clinical evaluations of the commercially pro-
duced LAM ELISAs have been published to date using
sputum culture as the gold standard [12,23,24,30-35]
(Table 1). Of these, 5 were done in South Africa and the
remainder in Tanzania (two studies), Zimbabwe and
India. The first of these studies published in 2005
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Table 1 Studies evaluating commercially available assays detecting urinary lipoarabinomannan (LAM) for diagnosis of tuberculosis (TB) in patients with
culture-confirmed disease
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evaluated the Chemogen assay in Tanzania and found a
moderately high sensitivity (74–81%) and very high spe-
cificity (99%) both among HIV-infected and non-
infected ambulatory patients with pulmonary TB [30].
No study has since replicated these data and the reasons
for this remain unclear.
Subsequent evaluations in HIV-noninfected patients
have found the assay sensitivity for sputum culture-posi-
tive TB to be very poor indeed (6%–21%) (Table 1). In
contrast, the sensitivity among HIV-infected TB patients
has been found to be greater (21%–67%). A key observa-
tion is that sensitivity is very strongly related to blood
CD4 cell count, with higher sensitivity observed at lower
CD4 cell counts (Figure 2). Among patients with CD4
cell counts <50 cells/μL, sensitivity has ranged between
56% and 85% (Table 1), greatly exceeding the sensitivity
of sputum smear microscopy. When results of micros-
copy and the LAM ELISA are combined (either test
positive), there is incremental diagnostic sensitivity (Fig-
ure 2). This indicates that among patients with sputum
culture-positive TB, microscopy and LAM diagnose dif-
ferent sub-groups of individuals.
Reported specificity also varies between the 9 studies
(Table 1). Six of these studies (including all 5 from South
Africa) have found specificity to be 96%–100%. In con-
trast, studies from Tanzania, Zimbabwe and India
reported specificities of 88%–89%. The issue of variable
specificity between studies is very important and the range
of potential contributing factors is considered in detail
later in this article.
Development of a point-of-care LAM assay
The commercially available LAM ELISAs are 96-well
plate format sandwich assays that employ highly purified
polyclonal antibody preparations. This format of the
assay is not suitable for use in resource-limited settings
due to infrastructure limitations and the need for sample
preparation and batch processing in centralised labora-
tories. However, using the same antibody preparations, a
simple lateral-flow version of the assay has been pro-
duced as a point-of-care test (Figure 3). Determine TB-
LAM Ag ([Determine TB-LAM] Alere, Waltham, MA,
USA) is an immunochromatographic assay in which the
capture antibodies are adsorbed onto the nitrocellulose
membrane of the test strip and the detection antibody is
labelled by conjugation to colloidal gold particles.
The assay procedure is very simple. A volume of 60 μL
of unprocessed urine is added to the sample pad where
colloidal gold labelled antibodies bind to LAM present in
the sample (Figure 3). As the urine sample moves along
the test strip, complexed LAM is then captured by the
LAM antibodies immobilized in a line on the nitrocellulose
membrane. The colloidal gold particles result in the devel-
opment of a visible purple line, indicating the presence of
LAM in the sample (Figure 3). A control bar is also
included in the sample test strip to ensure assay validity.
The test strip is read between 25 and 35 minutes of incu-
bation at room temperature. The intensity of any visible
band is compared with the faintest positive line on the
reference card. Any line with similar or greater line inten-
sity is scored as testing positive for LAM. Thus, the assay
result is a qualitative (positive/negative) test for LAM.
Clinical evaluation of a point-of-care LAM assay
The first clinical evaluation of the Determine TB-LAM
assay was among HIV-infected patients with advanced im-
munodeficiency enrolling in an antiretroviral treatment
(ART) service in a South African township [12]. All eli-
gible patients were screened for TB regardless of the pres-
ence or absence of symptoms. Patients were classified as
either having TB (based on a diagnostic gold-standard of
culture-based detection of M. tuberculosis in one or more
sputum samples) or not having TB (based on negative
sputum cultures). The diagnostic accuracy of Determine
TB-LAM was also compared Xpert MTB/RIF - a simpli-
fied rapid molecular assay that was endorsed by the World
Health Organization in December 2010 as a replacement
for sputum smear microscopy in resource-limited settings
[36,37].
Urine samples obtained at the time of screening were
stored at −20°C and retrospectively tested in a laboratory
environment rather than prospectively at the point-of-
care [12]. Blinded assessments of the test strips by two
independent readers showed extremely high agreement
(к= 0.97). Results were very similar to those obtained by
the Clearview TB-ELISA run on the same samples
(к= 0.84), with marginally fewer false-negative and false-
positive results using the Determine TB-LAM test-strips.
In those with sputum culture-positive TB (n= 85), the
sensitivity of Determine TB-LAM stratified by CD4 cell
count (Figure 4) [12] was remarkably similar to that
observed using the Chemogen ELISA in the earlier study
conducted in the same study population (Figure 2) [31].
This is reassuring in that it demonstrates substantial
consistency in the performance of these LAM assays
which have been sequentially derived from one another
over the past 5 years. Although overall sensitivity was low
(28.2%), it was highest in those with the lowest CD4 count
categories (66.7% in those with CD4 counts <50 cells/μL).
Moreover, there was incremental sensitivity when results
of Determine TB-LAM and smear microscopy were com-
bined (either test positive), attaining a sensitivity of 72.2%
in those with CD4 cell counts <50 cells/μL. This was
comparable to the sensitivity of a single sputum Xpert
MTB/RIF test in this patient group (Figure 4).
Specificity of Determine TB-LAM was assessed in
patients with negative sputum cultures regardless of
clinical status (n = 431) and was 98.6% overall and
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exceeded 98% in all analyses stratified by CD4 cell count
and other patient characteristics [12]. The positive pre-
dictive value (PPV) exceeded 90% in all patients with
CD4 cell counts <150 cells/μL, those with a preceding
advanced WHO clinical stage (3 or 4) and among those
with chest radiographs that were reported as showing
any abnormality (however minor) that was consistent
with pulmonary TB. The negative predictive value of the
assay (89.8%) was not sufficient for reliable exclusion of
TB.
A second study by Peter and colleagues from South Af-
rica has evaluated Determine TB-LAM among hospital in-
patients [13]. Two groups of patients were recruited: HIV-
infected patients suspected of having TB (n= 335) and a
control group of HIV-infected patients with a non-TB
diagnosis (n= 88). An drawback of this study compared to
previous evaluations of LAM assays is that patients did
not undergo standardized investigation for TB by the
study team. Instead the results from investigations during
routine medical care were used, with samples being pro-
cessed in the routine laboratory system.
Data were analysed in a number of different ways. One
key finding was that when the faintest positive bands on
the test strips were used (grade 1 cut-point) as recom-
mended by the manufacturer, specificity in culture-negative
patients was very poor (66%, 95%CI, 57–74) but improved
to 96% (95%CI, 89–100) using the grade 2 cut-point [13].
Inter-observer agreement was also higher using the grade 2
cut-point. This finding differs from that of Lawn and collea-
gues [12] and this raises the possibility of variation between
different manufacturing lots of the test strips. No data have
yet been published examining batch to batch variation. An-
other possible explanation might be bacterial contamin-
ation of urine samples, giving rise to weak false-positive
bands as discussed later in this article.
Sensitivity was assessed using two different analyses, first
using a culture-based gold-standard and, second, a gold
standard that additionally incorporated clinico-radiological
diagnoses with a positive response to TB treatment [13].
Data were not stratified by CD4 cell count, but overall De-
termine TB-LAM had a sensitivity of 45% compared to
the composite gold standard and 71% when results were
combined with those of sputum smear microscopy.
Potential utility of determine TB-LAM point-of-care assay
The attractive features of Determine TB-LAM are that it
can be used at the point-of-care within an out-patient
clinic setting or on a hospital ward. Thus, patients can
be rapidly diagnosed (30 minutes per test) and treated at
a single clinic visit. It is low-cost (approximately $3.50


























Figure 2 Graph showing the sensitivity of a commercially
available enzyme-linked immunosorbent assay (ELISA) to
detect lipoarabinomannan (LAM) within urine samples to
diagnose tuberculosis (TB) in a cohort of patients accessing
antiretroviral treatment (ART) in a South African township. The
sensitivity (%) of sputum microscopy and the LAM ELISA are shown
individually and combined (either positive) compared with a gold
standard of automated liquid culture of two sputum samples. Data
are stratified by CD4 cell count (cells/μL) and show that the
sensitivity of the LAM ELISA was substantially greater in the patients
with the lowest CD4 cell counts. Figure reproduced from Lawn et al.




Figure 3 Photograph of a Determine TB-LAM test strip showing
the sample pad to which 60 μL of the test urine is applied.
After 25–35 minutes of incubation at room temperature, the control
band is checked and the sample test result is read. Reading may be
facilitated by comparison to the reference card. The presence of a
band in the sample window of similar or greater intensity to the
weakest positive on the reference card indicates the presence of
lipoarabinomannan (LAM) in the urine.
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for an Xpert MTB/RIF assay or over $20 for automated
liquid culture. The assay can be used by health care
workers with no laboratory training and without need
for any diagnostic hard-ware or electricity supply. It does
not generate large volumes of biohazardous waste and
the test strips can be stored at room temperature.
The assay only has utility in those with HIV infection
and advanced immunodeficiency (CD4 cell counts <200
cells/μL and/or WHO stage 3 or 4 disease) and therefore
should not be used to test unselected TB suspects attend-
ing medical out-patient clinics or TB clinics. Instead, the
assay should be targeted for use in those with known HIV
infection being screened for TB prior to starting ART or
requiring admission to hospital medical in-patient wards.
Since the assay sensitivity is so strongly associated with
blood CD4 cell count, it would best be used in patients
with CD4 cells counts known to be <200 cells/μL. This is
a draw-back for resource-limited settings where CD4
count testing may not routinely be available.
Determine TB-LAM would ideally be used in combin-
ation with other diagnostic assays, providing incremental
diagnostic sensitivity and/or expediting diagnosis to per-
mit TB treatment to be started at a single clinic visit.
The potential advantages of various combinations of
assays are shown in Table 2. Smear microscopy alone is
the mostly widely available testing strategy in resource-
limited settings and use of Determine TB-LAM in com-
bination would increase diagnostic sensitivity without
great additional cost (Figure 4). This would permit rapid
diagnosis in those with the most advanced immunodefi-
ciency and highest mortality risk.
Chest radiography permits rapid patient evaluation, but
the radiological features of HIV-associated TB in those
with CD4 cell counts <200 cells/μL are often very non-
specific [4,38] and the differential diagnosis can be difficult
and time-consuming to resolve. However, the positive pre-
dictive value of Determine TB-LAM for TB was found to
be high among those with radiographic abnormalities [12]
and thus combined testing would increase diagnostic spe-
cificity in those with abnormal radiographs.
Mycobacterial culture is available in very few resource-
limited settings, but is invaluable for accurate diagnosis
Table 2 Utility of Determine TB-LAM point-of-care assay when used in combination with other diagnostic tests for
HIV-associated tuberculosis (TB)
Combination of diagnostic tests Advantages
Sputum smear microscopy + Determine TB-LAM • Incremental sensitivity.
• Smear microscopy diagnoses most infectious patients
• Determine TB-LAM provides rapid point-of-care diagnosis in
those with high mortality risk permitting immediate initiation of TB treatment.
• Low-cost.
Chest radiology + Determine TB-LAM • Determine TB-LAM can provide rapid point-of-care assessment
of patients with abnormal chest radiographs, increasing the specificity for TB diagnosis.
• Small incremental cost to radiology.
Sputum culture + Determine TB-LAM • Determine TB-LAM greatly expedites TB diagnosis in the sickest patients with highest
mortality risk.
• Small incremental cost to culture.
Sputum Xpert MTB/RIF + Determine TB-LAM • Determine TB-LAM adds little diagnostic sensitivity when used with Xpert MTB/RIF,
but provides rapid point-of-care assessment. When Xpert is located in laboratories
precluding same-day testing, Determine TB-LAM will expedite TB treatment in those
with highest mortality risk, allowing immediate initiation of TB treatment.































Diagnostic sensitivity of LAM point-of-care assay used alone or
in combination with other assays
Figure 4 Graph showing the diagnostic sensitivity for sputum
culture-positive tuberculosis using the Determine TB-LAM assay
for lipoarabinomannan (LAM) when used alone or in combination
with other diagnostics, including sputum smear microscopy
(smear) and Xpert MTB/RIF (Xpert). Data are stratified by CD4 cell
count (cells/μL) and show that the sensitivity of the LAM was
substantially greater in the patients with the lowest CD4 cell counts.
There was important incremental sensitivity when microscopy and
Determine TB-LAM were combined and this was similar to the
sensitivity of Xpert in patients with the lowest CD4 cell counts.
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of smear-negative TB. The very long time to culture-
based diagnosis in such patients (3 weeks in a study in
South Africa [31]) is a major draw-back, however, and
this delay would be greatly reduced in a proportion of
the patients with highest mortality risk by combined use
of Determine TB-LAM screening
In some countries such as South Africa, the Xpert
MTB/RIF assay is being implemented nationwide to
replace sputum smear microscopy as the first diag-
nostic assay. Determine TB-LAM provides little in-
cremental sensitivity when used in combination with
Xpert MTB/RIF [12] (Figure 4), and yet this combin-
ation may have an important advantage over use of
Xpert MTB/RIF in isolation. Due to feasibility, cost
and logistical issues, the Xpert MTB/RIF is likely to
be implemented in centralised laboratories, leading
to a critical disconnect between the patient and the
test results. This is problematic. In a study in Cape
Town, South Africa, where Xpert MTB/RIF is being
rolled out in centralised laboratories, only 76.6% of
patients diagnosed as having Xpert-positive TB dur-
ing pre-ART screening started TB treatment [26,39].
Moreover, these patients only started TB treatment
after a median delay of 9 days (interquartile range,
6–18 days) [26]. This delay was due to an overall
turnaround time of 4 days for the sample to reach the
laboratory, be processed, and for the results to be
issued and reach the clinic. Additional delays accrued
waiting for patients to return following recall; others
were found to have already died or were lost to follow-
up. Determine TB-LAM could close this treatment gap
for the patients who have the lowest CD4 cell counts
and highest mortality risk, permitting TB treatment
initiation at the first clinic visit.
There is currently much interest in development of strat-
egies to reduce early mortality in ART programmes in sub-
Saharan Africa [40], and TB is recognised as one of the key
causes of death [41]. In the absence of suitable diagnostics,
trials have been designed to evaluate a strategy whereby
HIV-infected patients in high TB prevalence settings with
very low CD4 counts but no overt TB diagnosis are rando-
mised to receive or not receive empiric TB treatment, with
mortality being the primary outcome of interest [42]. These
are multicentre trials are being conducted in sub-Saharan
Africa and include the AIDS Clinical Trial Group (ACTG)
REMEMBER trial (NCT01380080) and the PROMPT study
(NCT01417988) funded by the European Developing
Countries Clinical Trials Programme (EDCTP). However,
the recent emergence of the Determine TB-LAM assay has
to some extent undermined the rationale for such studies
Table 3 Further research that is needed regarding the Determine TB-LAM assay
Focus of research Goal Studies needed
Assay and samples Understanding the assay Determine mechanisms by which LAM enters urine.
Further clarify the host and pathogen factors
associated with LAM antigenuria
Assess any batch to batch variation of the assay To determine manufacturing quality control of the test strips
Improve diagnostic accuracy Research and development to identify means to improve
sensitivity and specificity
Studies to assess and enhance
reproducibility of interpreting test strips
Assess impact of conditions of sample storage Determine the effect of duration of urine storage at room
temperature and any impact of freeze-thaw cycles on
diagnostic accuracy
Assess impact of urine contamination Assess impact of contamination of urine samples on specificity
Diagnostic accuracy
and assay utility
Assess diagnostic accuracy More studies are needed to very carefully assess the
sensitivity and specificity in different geographical locations in
appropriate clinical populations (advanced HIV, ambulatory vs
hospitalized, adults vs children) using appropriate diagnostic
gold standard.
Assess for any association between reduced
specificity and non-tuberculous mycobacteria or other
coinfections/co-morbidity
Use by health care workers at point-of-care Assess feasibility and acceptability of running and reading
the test-strips at point-of-care by non-laboratory trained
health-care workers
Incorporation in diagnostic algorithms Operational research to assess feasibility and utility of
incorporating in different diagnostic algorithms
Impact and cost Impact assessment Assess the impact on time to diagnosis, time to starting
TB treatment, morbidity and mortality and programme efficiency
Cost-effectiveness Assess cost-effectiveness in different settings
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in view of its ability to rapidly detect those with TB and
high mortality risk.
Further research
Many more studies on the Determine TB-LAM assay are
needed and a list of research questions that need to be
addressed is given in Table 3. These questions fall into
three main groups: 1) those related to gaining a better
understanding of the assay, improving its performance
and investigating optimum sample storage; 2) those asses-
sing diagnostic accuracy and issues surrounding imple-
mentation, and 3) those assessing impact and cost. A
robust evidence base is needed to permit public health
policy development with regards to implementation of this
assay.
Assay specificity: a key unresolved issue
Studies have consistently reported that the LAM assays
(ELISAs or point-of-care assay) have useful sensitivity in
HIV-infected patients with low CD4 cell counts
[12,24,31,34]. On this point, there is consensus. However,
the issue of assay specificity is not so clearly defined. Stud-
ies done within South Africa have all found specificity to lie
in the range 96% to 100% [12,24,31,34,35]. In contrast,
studies from Tanzania, Zimbabwe and India reported speci-
ficities of 88%–89% [23,32,33]. The reasons for this have
not been identified although factors that might have con-
tributed in part might be proposed. In the Zimbabwe study,
for example, solid rather than liquid culture was used which
may have limited the diagnostic sensitivity of the gold
standard [32]. Another of the studies investigated predom-
inantly HIV-noninfected patients, which is an non-recom-
mended (‘off-label’) indication for the assay [33]. Despite
this, however, low specificity was also seen in the HIV-
infected sub-groups included in the Tanzania and Zim-
babwe studies [23,32].
There are a range of possible reasons for low specificity
in some studies:
i) Sensitivity of the gold standard assay for TB diagnosis.
The best gold standard diagnostic assay for TB is liquid
culture, which has greater sensitivity than solid media
culture. However, the sensitivity of any culture method
may also vary between laboratories depending, for
example, on the intensity of the sputum
decontamination procedure, the supplements added to
the growth media and other variables. Thus, over-
decontamination of sputum samples, for example, may
lead to apparent false-positive LAM-antigenuria.
ii) Reliance on sputum samples for gold standard
diagnosis. All studies to date have relied on sputum
culture as the diagnostic gold standard except for the
study by Shah and colleagues which also included
mycobacterial blood cultures [34]. This is potentially
problematic for several reasons. Not all cases of HIV-
associated TB have pulmonary involvement yielding
positive respiratory samples [43]. Thus, patients with
HIV-associated TB may have negative sputum cultures
but nevertheless have LAM antigenuria. Also, poor
quality sputum samples may cause failure of TB
detection in patients who may nevertheless have LAM
antigenuria. Obtaining respiratory samples of sufficient
quality may be especially challenging in very sick
hospital in-patients. In such patients, cough strength
may be impaired and infection control hazards in the
ward environment may mitigate against good sputum
collection. In this regard, specificity might be expected
to appear lower in studies of in-patients rather than
ambulatory out-patients. Use of routine sputum
induction done on all study participants in an
appropriate clinical setting is likely to be needed as was
done in studies in a South African ART service
[12,31,44].
The microbiological gold-standard would be
considerably enhanced by examining both pulmon-
ary and extrapulmonary samples. Fine needle aspi-
rates of enlarged lymph nodes and urine samples
[25,43,45,46] might also be examined using culture
or the Xpert MTB/RIF assay and mycobacterial
blood cultures might be done to provide a compos-
ite microbiological gold standard. This, would make
studies somewhat more intensive both from clinical
and laboratory stand points.
iii)Use of clinical follow-up. The use of clinical
follow-up for suspecting or refuting a TB
diagnosis in the presence of negative
microbiology is problematic in HIV-infected
patients with advanced immunodeficiency.
Clinical follow-up may not be possible due to
death, the risk of which is high in this patient
population. Early ART initiation may alter the
clinical picture. In addition, a high rate of new
incident TB and frequent co-pathology often
confuses the clinical picture.
iv)Non-tuberculous mycobacteria. A key question is
whether non-tuberculous mycobacterial species
in vivo could cause LAM-antigenuria. As
discussed earlier, LAM encompasses large family
of related molecules which are expressed by all
mycobacterial species. Although M. tuberculosis
strains were the most strongly reactive, pre-
clinical studies in vitro did find cross-reactivity
between a range of mycobacterial strains
(including Mycobacterium fortuitum,
Mycobacterium kansasii, and Mycobacterium
bovis) when using the prototype ELISA
developed by Chemogen [30]. Similarly, a LAM
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ELISA system reported by Kadival and colleagues
also showed low-level cross reactivity with
Mycobacterium avium, M. kansasii and M.
fortuitum [47]. Thus, this is a possible reason for
lowered specificity of LAM assays and might
explain differences between studies in different
countries as the prevalence of these organisms
has substantial geographical variation.
In Table 1, the detection of non-tuberculous
mycobacteria during diagnostic accuracy studies is
shown but this was reported in just 4 of the 9 stud-
ies. The proportion of false-positive LAM results
that was associated with culture of non-tuberculous
mycobacteria from sputum ranged from zero [31]
to 4 out of 8 (50%) [35]. Of note, in the study from
Tanzania in which specificity of the Chemogen
MTB ELISA was just 88%, 4 of 14 (29%) false posi-
tives were associated with culture of non-tubercu-
lous mycobacteria. Whether these associations are
causal (ie associated with invasive non-tuberculous
mycobacterial disease and LAM-antigenuria) or
whether these organisms are simply colonisers of
the airway or sputum contaminants is not yet
known. Non-mannosylated LAM molecules that are
more typical of non-tuberculous mycobacteria are
very strongly proinflammatory. Thus, it might be
expected that these forms of LAM would not be
present in the systemic circulation in sufficient con-
centrations in an uncomplexed form that could
then result in detectable antigenuria. Careful re-
search on this issue is needed.
v) Urine sample contamination. It is known that the
anti-LAM antibodies used in the commercial LAM
assays cross-react with a number of non-
mycobacterial species. Dheda and colleagues
reported that cultures containing common oral flora
such as various species of Actinobacteria (strains of
Nocardia and Streptomyces) and Candida showed
reactivity in the Clearview TB ELISA [24]. It is not
inconceivable that the presence of similarly reactive
species on the perineum could contaminate urine
samples and lead to false-positive tests, especially if
samples were left for periods at room temperature
permitting replication of these organisms. Similarly,
it is likely to be important that urine is collected and
stored in sterile containers.
Conclusions
The Determine TB-LAM assay is the first point-of-care
assay for TB and this has been found to have specific utility
in those with advanced HIV-associated immunodeficiency.
These are the very patients who could potentially gain the
most from rapid point-of-care diagnosis, permitting
initiation of TB treatment at a single clinic visit. The first
clinical evaluation in the field [12] was very encouraging al-
though a second study reported more difficulties in reading
of the test strips [13]. There is a strong rationale to push
ahead with many more studies. These should further evalu-
ate diagnostic accuracy in a range of geographical settings;
assess utility and feasibility in in-patient and ambulatory
out-patient clinical populations, including children; deter-
mine how best to incorporate the assay within diagnostic
algorithms and assess cost and impact. This assay might
potentially have been discarded on the basis of apparent
sub-optimal sensitivity. However, with studies in appropri-
ate clinical populations providing new insights into the real
utility of this assay, the assay is now emerging as an import-
ant tool that may serve to greatly expedite TB diagnosis
and treatment in those with advanced HIV-associated im-
munodeficiency, potentially reducing mortality risk.
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